Related Experiment Video

Updated: Aug 15, 2026

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Discovery of ZJC-11 as a Novel Selective CDK7 Inhibitor for Treating Triple-Negative Breast Cancer by Inducing Cell

Bo Chen1,2,3,4, Lihong Wu1,2, Limei Zhang1,2

  • 1Department of Pharmacology, College of Pharmacy, Chongqing Medical University, Chongqing400016, China.

Journal of Medicinal Chemistry
|August 13, 2026
PubMed

Insights

A novel compound, ZJC-11, shows potent activity against triple-negative breast cancer (TNBC) by targeting cyclin-dependent kinase 7 (CDK7). This inhibitor effectively reduces tumor growth and toxicity, offering a promising new therapeutic avenue for TNBC patients.

Area of Science:

  • Oncology
  • Medicinal Chemistry
  • Molecular Biology

Background:

  • Triple-negative breast cancer (TNBC) remains a challenging subtype with limited targeted therapies.
  • Cyclin-dependent kinase 7 (CDK7) is an emerging target for cancer treatment, particularly in TNBC.
  • Existing CDK7 inhibitors face challenges with toxicity and efficacy.

Purpose of the Study:

  • To design, synthesize, and evaluate novel small molecules targeting CDK7 for TNBC treatment.
  • To identify a potent and selective CDK7 inhibitor with improved therapeutic profile.
  • To elucidate the mechanism of action of the lead compound in TNBC cells.

Main Methods:

  • Synthesis and chemical characterization of 21 novel CDK7 inhibitors.
  • In vitro and in vivo evaluation of antiproliferative activity against TNBC cell lines and xenografts.
  • Molecular docking, Kinact/KI assays, kinase selectivity profiling, and pharmacokinetic studies.
  • RNA sequencing and functional assays to determine molecular mechanisms.
  • Combination studies with doxorubicin and assessment of cardiotoxicity.

Main Results:

  • ZJC-11 identified as a potent lead candidate, demonstrating significant antiproliferative effects against TNBC in vitro and in vivo.
  • ZJC-11 selectively and covalently targets CDK7 with favorable pharmacokinetics and reduced toxicity compared to THZ1.
  • Mechanism involves suppression of transcription, G2/M cell cycle checkpoint, and induction of DNA damage-driven senescence, leading to cell death.
  • ZJC-11 showed synergistic effects with doxorubicin and alleviated doxorubicin-induced cardiotoxicity.

Conclusions:

  • ZJC-11 is a promising therapeutic candidate for TNBC, offering potent anti-tumor activity and improved safety profile.
  • The dual action of inhibiting transcription/cell cycle and inducing DNA damage contributes to ZJC-11's efficacy.
  • ZJC-11's ability to mitigate doxorubicin cardiotoxicity presents a significant clinical advantage for TNBC treatment strategies.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.